GCB-27a 

GCB-27a is a CD1d-binding immunostimulant and antitumor agent. GCB-27a binds to CD1d to form a stable complex and presents it to NKT cells, enhancing hydrophobic interactions within the A' pocket of CD1d through branched-chain conformation restriction. GCB-27a induces a Th1-biased immune response, drives IFN−γ production and limits IL-4 levels. GCB-27a is applicable to research related to melanoma lung metastasis^[1].

GCB-27a (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with elevated IFN-γ secretion across all tested concentrations and no associated cytotoxicity^[1].
GCB-27a (100 nM; 2-24 h) forms more stable and sustained complexes with mouse CD1d on BMDC surfaces than αGalCer, as measured by enhanced and prolonged L363 antibody binding^[1].
GCB-27a (24 h) potently induces Th1-biased cytokine production in human NKT cells, with a 2-fold higher frequency of IFN-γ⁺ cells than αGalCer and comparable IL-4 induction^[1].
GCB-27a has stronger binding affinity for both human and murine CD1d than αGalCer, due to optimized hydrophobic interactions and conformational preorganization within the CD1d A' pocket^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GCB-27a (2.33 nmol per mouse; i.p.; single injection) induces a potent Th1-biased immune response in BALB/c mice, with a 10.9-fold higher IFN-γ level relative to αGalCer while maintaining comparable IL-4 levels^[1].
GCB-27a (2.33 nmol per mouse; i.p.; single injection) potently activates innate immune cells in C57BL/6 mice, enhancing DC maturation marker expression and increasing the frequency of IFN-γ-secreting NK cells^[1].
GCB-27a (0.58 nmol per mouse; i.p.; single injection) exhibits potent antitumor efficacy in a murine melanoma lung metastasis model, reducing metastatic nodule counts by 89% relative to αGalCer via a sustained Th1-biased immune response^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

894.31

C₅₂H₉₅NO₁₀

O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCC)CCCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wen Y, et al. Highly Potent Th1-Type NKT Cell Agonists as Immunotherapeutic Agents via Conformational Restriction Design. JACS Au. 2026;6(2):1171-1184. Published 2026 Feb 6.  [Content Brief]